Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benny Barnhart

Psychiatry Wichita Falls, TX Medical Doctor

NPI 1871571075 CMS profile 357813

501 Midwestern Pkwy E, Wichita Falls, TX 76302

Open in the dashboard

General payments

$7,188

361 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,350,206 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Benny Barnhart of Wichita Falls, TX is reported in the CMS Open Payments database as having received $7,188 across 361 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,350,206 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $900 42
2024 General $735 37
2023 General $1,053 62
2022 General $1,154 67
2021 General $1,244 77
2020 General $575 39
2019 General $1,527 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benny Barnhart
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Benny Barnhart were reported at $900. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Benny Barnhart Psychiatry median Middle half National median
2019 $1,527 $184 $59–$605 $163
2020 $575 $119 $36–$372 $114
2021 $1,244 $143 $43–$576 $132
2022 $1,154 $153 $50–$590 $149
2023 $1,053 $170 $56–$651 $160
2024 $735 $179 $57–$673 $164
2025 $900 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,124 9 payments
  2. Otsuka America Pharmaceutical, Inc. $831 50 payments
  3. AbbVie, Inc. $692 41 payments
  4. Teva Pharmaceuticals USA, Inc. $681 31 payments
  5. Neurocrine Biosciences, Inc. $570 30 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $443 30 payments
  7. Supernus Pharmaceuticals, Inc. $391 22 payments
  8. Tris Pharma Inc $389 22 payments
  9. ITI, Inc. $292 18 payments
  10. Avanir Pharmaceuticals, Inc. $282 16 payments
  11. Other $1,495 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,045 358 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
  3. Education $143 2 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $1,124 9 payments
  2. REXULTI $793 48 payments
  3. VRAYLAR $477 29 payments
  4. QELBREE $391 22 payments
  5. Dyanavel XR $389 22 payments
  6. INGREZZA $375 19 payments
  7. TRINTELLIX $305 19 payments
  8. CAPLYTA $292 18 payments
  9. ABILIFY MAINTENA $288 15 payments
  10. NUEDEXTA $282 16 payments
  11. Other $3,778 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

4,027

Median for Psychiatry: 574

Drug cost

$437,433

Median for Psychiatry: $27,624

Branded share of claims

17.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 18 $142,561
Aristada Aripiprazole Lauroxil Brand 13 $42,774
Caplyta Lumateperone Tosylate Brand 20 $34,578
Vraylar Cariprazine Hcl Brand 19 $27,207
Rexulti Brexpiprazole Brand 14 $22,134
Nuedexta Dextromethorphan Hbr/Quinidine Brand 13 $21,338
Belsomra Suvorexant Brand 30 $18,424
Trintellix Vortioxetine Hydrobromide Brand 15 $16,863
Lisdexamfetamine Dimesylate Generic 56 $10,972
Clozapine Generic 57 $9,946

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$172,530

Medicare's payments for the services billed

Medicare patients

304

Average age 70

Services billed

2,713

205 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 62%
Diabetes 38%
Ischemic heart disease 28%
Chronic kidney disease 27%
Heart failure 24%
Alzheimer's or dementia 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $113
$113 — —
VRAYLAR
  • AbbVie, Inc. $97
$97 19 —
Dyanavel XR
  • Tris Pharma Inc $74
$74 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $48
  • Lundbeck LLC $14
$62 14 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $62
$62 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

361 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record